XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 02, 2021
Sep. 30, 2024
USD ($)
jurisdiction
Jul. 31, 2024
USD ($)
candidate
aqua_facility
Mar. 31, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jan. 31, 2023
USD ($)
Sep. 30, 2024
USD ($)
jurisdiction
Dec. 31, 2023
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
jurisdiction
Sep. 30, 2023
USD ($)
Apr. 30, 2024
candidate
Oct. 31, 2023
USD ($)
candidate
Feb. 28, 2023
candidate
Business Acquisition [Line Items]                            
Research and development             $ 5,862   $ 3,307 $ 13,354 $ 20,904      
Sales             16,657   15,962 48,544 45,485      
Cost of sales             4,080   4,264 11,365 12,214      
Other current assets   $ 8,143         8,143 $ 8,368   8,143        
Accrued and other current liabilities   16,539         16,539 15,766   16,539        
Related Party                            
Business Acquisition [Line Items]                            
Other current assets   370         370 632   370        
Accrued and other current liabilities   $ 130         130 598   130        
Manufacturing and Supply Agreements | Related Party                            
Business Acquisition [Line Items]                            
Sales             109   100 309 290      
Cost of sales             $ 108   106 $ 310 314      
Minimum | Manufacturing and Supply Agreements | Related Party                            
Business Acquisition [Line Items]                            
Period of continuing involvement after disposal 4 years                          
Maximum | Manufacturing and Supply Agreements | Related Party                            
Business Acquisition [Line Items]                            
Period of continuing involvement after disposal 10 years                          
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Organon & Co.                            
Business Acquisition [Line Items]                            
Number of jurisdictions remaining | jurisdiction   1         1     1        
Orion                            
Business Acquisition [Line Items]                            
Eligible future contingent development-related payments (up to)     $ 30                      
Eligible future contingent regulatory milestone payments (up to)     625                      
Eligible future contingent sales-based milestone payments (up to)     $ 975                      
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                            
Business Acquisition [Line Items]                            
Research and development             $ 94 5,500 0 $ 227 0      
Number of antibody drug conjugates obtained right and obligations | candidate                         3  
Accrued and other current liabilities   $ 811         811 $ 800   811        
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                            
Business Acquisition [Line Items]                            
Eligible future contingent development-related payments (up to)                         $ 540  
Eligible future contingent regulatory milestone payments (up to)                         1,500  
Eligible future contingent sales-based milestone payments (up to)                         $ 3,100  
Number of antibody drug conjugates | candidate                           7
Upfront payment made to collaborative partner                 $ 175   175      
Number of antibody drug conjugates terminated | candidate                       1 2  
Number of exercised license option antibody drug conjugates | candidate     1                      
Number of licensed antibody drug conjugates | candidate     3                      
Number of unexercised license option antibody drug conjugates | candidate     1                      
Payment resulting from the license option exercise     $ 38                      
Stock investment in counterparty           $ 100                
Elanco Animal Health Incorporated Aqua Business                            
Business Acquisition [Line Items]                            
Payment to acquire business     $ 1,300                      
Aqua manufacturing facilities | aqua_facility     2                      
CN201, Curon Biopharmaceutical                            
Business Acquisition [Line Items]                            
Consideration transferred, asset acquisition   700                        
Future contingent developmental milestone payments (up to)   300         300     300        
Future regulatory milestone payments (up to)   300         300     300        
Research and development             750     750        
CN201, Curon Biopharmaceutical | Third-Party                            
Business Acquisition [Line Items]                            
Aggregate contingent developmental, regulatory, and sales-based-related payments   $ 128         128     128        
Eyebiotech Limited                            
Business Acquisition [Line Items]                            
Consideration transferred, asset acquisition     $ 1,200                      
Future contingent developmental milestone payments (up to)     200                      
Future regulatory milestone payments (up to)     1,000                      
Research and development             1,350     1,350        
Asset acquisition, transaction costs     207                      
Developmental milestone payment triggered             100              
Maximum aggregate sales-based milestone payments     $ 500                      
Net assets acquired             $ 21     21        
Harpoon Therapeutics, Inc.                            
Business Acquisition [Line Items]                            
Consideration transferred, asset acquisition       $ 765                    
Research and development                   656        
Asset acquisition, transaction costs       $ 56                    
Net assets acquired                   $ 165        
Prometheus Biosciences, Inc.                            
Business Acquisition [Line Items]                            
Consideration transferred, asset acquisition         $ 11,000                  
Research and development                     10,200      
Net assets acquired         877                  
Consideration transferred, to settle share-based equity awards         1,200                  
Consideration transferred, to settle equity awards, unvested         700                  
Cash recorded for asset acquisition         368                  
Investments recorded for asset acquisition         296                  
Deferred tax assets recorded for asset acquisition         218                  
Other net liabilities recorded for asset acquisition         $ 5                  
Imago Bio Sciences, Inc.                            
Business Acquisition [Line Items]                            
Consideration transferred, asset acquisition           1,350                
Research and development                     $ 1,200      
Asset acquisition, transaction costs           60                
Net assets acquired           $ 219